Oncotarget

Research Papers:

Pseudogene BMI1P1 expression as a novel predictor for acute myeloid leukemia development and prognosis

Ling-Yu Zhou, Ling-Ling Zhai, Jia-Yu Yin, Minse Evola-Deniz Vanessa, Jiao Zhou, Jing Zhang, Xi Tang, Jiang Lin, Jun Qian and Zhao-Qun Deng _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:47376-47386. https://doi.org/10.18632/oncotarget.10156

Metrics: PDF 1723 views  |   HTML 1757 views  |   ?  


Abstract

Ling-Yu Zhou1,2, Ling-Ling Zhai1,2, Jia-Yu Yin1,2, Minse Evola-Deniz Vanessa1, Jiao Zhou1,2, Jing Zhang1,2, Xi Tang1,2, Jiang Lin1, Jun Qian2, Zhao-Qun Deng1

1Department of Laboratory Center, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People’s Republic of China

2Department of Hematology, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People’s Republic of China

Correspondence to:

Zhao-Qun Deng, email: [email protected]

Jiang Lin, email: [email protected]

Keywords: pseudogene, acute myeloid leukemia, BMI1P1, tumor marker

Received: April 05, 2016     Accepted: June 06, 2016     Published: June 18, 2016

ABSTRACT

The BMI1P1 levels of 144 de novo AML patients and 36 healthy donors were detected by real-time quantitative PCR (RQ-PCR). BMI1P1 was significantly down-regulated in AML compared with control (P < 0.001). A receiver operating characteristic (ROC) curve revealed that BMI1P1 expression could differentiate patients with AML from control subjects (AUC = 0.895, 95% CI: 0.835–0.954, P < 0.001). The percentage of blasts in bone marrow (BM) was significantly lower in BMI1P1 high-expressed group versus low-expressed group (P = 0.008). BMI1P1 high-expressed cases had significantly higher complete remission (CR) than BMI1P1 low-expressed cases (P = 0.023). Furthermore, Kaplan–Meier demonstrated that both whole AML cohort and non-M3-AML patients with low BMI1P1 expression showed shorter leukemia free survival (LFS, P = 0.002 and P = 0.01, respectively) and overall survival (OS, P < 0.001 and P = 0.011, respectively) than those with high BMI1P1 expression. Multivariate analysis also showed that BMI1P1 over-expression was an independent favorable prognostic factor for OS in both whole and non-M3 cohort of AML patients (HR = 0.462, 95% CI = 0.243–0.879, P = 0.019 and HR = 0.483, 95% CI = 0.254–0.919, P = 0.027). To further investigate the significance of BMI1P1 expression in the follow-up of AML patients, we monitored the BMI1P1 level in 26 de novo AML patients and found that the BMI1P1 level increased significantly from the initial diagnosis to post-CR (P < 0.001). These results indicated that BMI1P1 might contribute to the diagnosis of AML and the assessment of therapeutic effect.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10156